A cohort study on the association of MDM2 SNP309 with lung cancer risk in Bangladeshi population

Hasan Al Reza¹, Wardatul Jannat Anamika¹, Md. Miraj Kobad Chowdhury¹, Mohammad Golam Mostafa², and M. Aftab Uddin¹

¹Department of Genetic Engineering and Biotechnology, University of Dhaka, Dhaka; ²Department of Histopathology, National Institute of Cancer Research and Hospital, Dhaka, Bangladesh

Background/Aims: Bangladesh is a densely populated country with an increased incidence of lung cancer, mostly due to smoking. Therefore, elucidating the association of mouse double minute 2 homolog (MDM2) single nucleotide polymorphism (SNP) 309 (rs2279744) with lung cancer risk from smoking in Bangladeshi population has become necessary.

Methods: DNA was extracted from blood samples of 126 lung cancer patient and 133 healthy controls. The MDM2 SNP309 was genotyped by polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP), using the restriction enzymes MspA1I. Logistic regression was then carried out to calculate odds ratios (ORs) and 95% confidence intervals (CIs) to estimate the risk of lung cancer. A meta-analysis of SNP309 was also carried out on 12,758 control subjects and 11,638 patient subjects.

Results: In multivariate logistic regression, significantly increased risk of lung cancer was observed for MDM2 SNP309 in the dominant model (TG + GG vs. TT: OR, 2.13; 95% CI, 1.29 to 3.53). Stratification analysis revealed that age, sex, obesity, and smoking also increases the risk of lung cancer when carrying the MDM2 SNP309. Our meta-analysis revealed that MDM2 SNP309 was considerably associated with lung cancer in Asian populations (TG + GG vs. TT: OR, 1.32; 95% CI, 1.12 to 1.56; p = 0.019 for heterogeneity).

Conclusions: The MDM2 SNP309 was associated with high risk of lung cancer in Bangladeshi and Asian population, particularly with increased age, smoking, and body mass index.

Keywords: Lung neoplasms; MDM2 gene; MDM2 SNP309; Meta-analysis

INTRODUCTION

Bangladesh is one of the most densely populated countries with an average population of 168 million people. In Bangladesh, an estimated 0.19 million people suffer from lung cancer each year. The death rate due to lung cancer is approximately 0.03 million per year. Smoking is by far the most strongly correlated risk factor for lung cancer. About 90% of lung cancer cases are caused by tobacco usage, and 80% of lung cancer deaths are as a direct result of smoking tobacco [1]. Lung cancer occurs more in the elderly than in the young [2]. About 67% of people diagnosed with lung cancer are of age 65 years or older, while less than 2% are younger than 45 years of age.
The odds of a man developing lung cancer is about 1 in 14, while the odds of a woman developing lung cancer is 1 in 17 [5,6]. Carreras-Torres et al. [7] report that for every 4.6 kg/m² increase in body mass index (BMI), the risk of squamous cell carcinoma increases by 1.20.

MDM2, the mouse double minute 2 homolog, is a E3 ubiquitin-protein ligase encoded by the MDM2 gene in humans [8]. MDM2 is a p53-inducible gene. MDM2 and p53 are linked together by an autoregulatory negative feedback loop, which aims to maintain low cellular levels of p53 in the absence of cellular stress [9]. It is a negative regulator of p53 tumor suppressor and inhibits the transcriptional trans-activation mediated by p53. It recognizes the N-terminal trans-activation domain (TAD) of p53, and ubiquitinylates p53 for proteosomal degradation.

We have previously shown that P53 codon 72 single-nucleotide polymorphism increases the risk of lung cancer in Bangladeshi patients [10]. Evidence also suggests that the MDM2 single nucleotide polymorphism (SNP) 309 T>G (rs2279744) increases the risk of lung cancer [11]. But these suggestions have never been explored in the Bangladeshi population. Here, we have elucidated the distribution of the MDM2 SNP309 in the Bangladeshi population. We have attempted to evaluate the effect of this SNP on the risk of lung cancer in general and have linked the factors those can contribute to such risk.

**METHODS**

**Statement of ethics**

The study was approved by the ethical clearance board of National Institute of Cancer Research and Hospital (NICRH), Dhaka Medical College and Hospital (DMCH), and the University of Dhaka, Bangladesh (IRB No. 53/Biol.Scs./2017-18). Before proceeding with the study, the subjects were notified about the experiments and written informed consent was obtained from everyone. The experimental procedures involved in the study were carried out in accordance with standard approved guidelines.

**The study subjects**

A total of 126 patient test subjects were contacted at the NICRH. Among them, 18 patients were with small cell lung carcinoma, 33 with adenocarcinoma, and the rest 75 were diagnosed with squamous cell lung carcinoma. In addition, 133 healthy control subjects were contacted at the Institute of Nuclear Medicine and Allied Science, DMCH, Dhaka. The patients were asked some questions in a small interview and requested to complete a structured questionnaire to collect the demographic information. The signed informed consent form was collected along with 5 mL of venous blood samples in purple top ethylenediaminetetraacetic acid vacutainers. The tubes were then transported to the laboratory in an ice-box.

**DNA extraction and genotyping**

Blood samples were stored at –20°C. Genomic DNA was extracted from samples using GeneJET Genomic DNA Purification Kit (Thermo Scientific, Waltham, MA, USA) following the manufacturer’s protocol. The DNA samples were quantified by using NanoDrop Spectrophotometer (NanoDrop 1000, Thermo Scientific) and were stored at –20°C for future use.

A 352 bp DNA fragment around the MDM2 SNP309 was amplified by polymerase chain reaction (PCR) using the primer set: 5′-CGGGAGTTCAGGGTAAAGGT-3′ and 5′-AGCAAGTGGCTTACCTG-3′. PCR reactions were carried out in a 20 µL reaction mixture containing 2 µL (50 to 100 ng) DNA sample, 1 µL (10 pmol) of each primer, 6 µL of nanopore water, and 10 µL GoTaq Colorless Master Mix (Promega Corp., Madison, WI, USA) in a GeneAtlas G thermal cycler (Astec Co. Ltd., Fukuoka, Japan). The PCR steps were as follows: an initial denaturation step (95°C, 5 minutes), followed by 40 cycles of denaturation (95°C, 30 seconds), annealing (61°C, 30 seconds), and elongation (72°C, 1 minute) steps, followed by a final elongation step (72°C, 5 minutes). The amplified fragments were visualized in a 1% agarose gel. These amplicons were then purified using GeneJET PCR Purification Kit (Thermo Scientific) following the manufacturer’s protocol.

The genetic profiling of the MDM2 SNP309 gene was carried out by restriction fragment length polymorphism (RFLP). The 352 bp amplicons for MDM2 SNP309 were digested using MspA1I (New England Biolabs, Beverly, MA, USA) according to the manufacturer’s protocol. The digested products were separated by electrophoresis in a 1.8% agarose gel in 1X TBE. The
unique fragmentation patterns were then visualized under ultraviolet-transilluminator by staining the gel with ethidium bromide.

**Statistical analyses**
All statistical analyses were performed using the statistical software package Stata version 14.1 (StataCorp., College Station, TX, USA). The data obtained from the questionnaires were analyzed to identify differences between the patient and control demographic characteristics. Continuous variables such as age and BMI were tested using Student’s t test, while categorical variables such as sex and smoking status were tested using Pearson chi-square test. Smoking history of patients and controls was compared using the Wilcoxon rank-sum test to find any significant difference. The genotypes were tested for the Hardy-Weinberg equilibrium. Test for trend was also carried out on the distribution of the SNP across the ordered groups. The odds ratio (OR) and 95% CI (confidence interval) were calculated for the SNP genotypes using simple logistic regression by keeping the co-dominant, dominant and recessive model in mind. Adjusted OR and 95% CI were then calculated to account for the confounding factors of age, sex, BMI, and smoking using multiple logistic regression analyses.

**Meta-analysis**
Case-control or cohort studies containing MDM2 SNP309 genotype distributions were searched through August 2017 in the PubMed and Google Scholar databases and 14 studies consisting of 12,625 control and 11,512 patient genotypes was selected for meta-analysis [12-25]. To determine the strength of the association, we calculated the OR and 95% CI of each study in the co-dominant, dominant, and recessive model. We also pooled the data to calculate overall OR and 95% CI. Subgroup analysis was performed by ethnicity. Z tests were used to determine the significance of the association between the SNP and lung cancer risk. The heterogeneity of the study was assessed by calculating Cochrane’s Q test, and I squared statistics. If the p value of the test was < 0.1, the random-effects model was used, otherwise the Mantel-Haenszel fixed-effects model was used [26]. Finally, publication bias was assessed by Begg’s rank correlation test and Egger’s linear regression test [27,28].

**RESULTS**

**Study characteristics**
There were no significant differences between the patients and the control subjects in case of demographic characteristics, except for smoking history. The pack years for patients and controls were 17.32 ± 18.60 and 10.87 ± 16.17, respectively, which was significantly different (p = 0.001). No significant differences were found between patients and controls for age (p = 0.675), BMI (p = 0.902), sex (p = 0.170), and smoking status (p = 0.051) (Table 1). Consequently, only the variables age, sex, BMI, and smoking status were adjusted for the multiple logistic regression analyses.

**Association of MDM2 SNP309 with lung cancer risk**
The allele distributions of the MDM2 SNP309 in the patient and control groups were in Hardy-Weinberg equilibrium (chi-square = 0.43, p = 0.514 for control; and chi-square = 1.56, p = 0.212 for control, respectively) (Table 2). For the control group the genotype frequencies of the alleles TT, TG, and GG were 56.4%, 34.6%, and 9% respectively, and for the patient group, the genotype frequencies were 37.3%, 45.2%, and 17.5% respectively. We have observed a significant difference in genotype and allele frequencies between the patient group and the control group in a Pearson’s chi-square test (chi-square = 10.36, p = 0.006).

Multivariate logistic regression was then carried out by adjusting for age, sex, BMI, and smoking status to account for their confounding factors in the analyses. It was revealed that individuals bearing the TG or GG genotype were at an increased risk of lung cancer [TG vs. TT: OR, 1.93; 95% CI, 1.12 to 3.33], [GG vs. TT: OR, 2.84; 95% CI, 1.27 to 6.34], when compared to the TT genotype. In the dominant model, individuals carrying either TG or GG were more susceptible to lung cancer (TG + GG vs. TT: OR, 2.13; 95% CI, 1.29 to 3.53), when compared to people carrying TT genotype, but with greater significance (p = 0.003). However, the recessive model was not significant (p = 0.053) (Table 3).

A stratification analysis was then carried out to see the effect of the grouped variables on the association between SNP309 and risk of lung cancer. All the values were calculated by using a dominant model and multiple logistic regressions adjusted for age, sex, BMI, and
smoking status. People over the age of 60 (TG + GG vs. TT: OR, 3.10; 95% CI, 1.09 to 8.85), male individuals (TG + GG vs. TT: OR, 2.24; 95% CI, 1.18 to 4.26), overweight people (TG + GG vs. TT: OR, 2.28; 95% CI, 1.14 to 4.37), and smokers (TG + GG vs. TT: OR, 2.77; 95% CI, 1.36 to 5.68) were at a statistically significant risk. However, we did not find any significant association between MDM2 SNP309 and lung cancer risk according to the pathological subtypes of lung cancer (Table 4).

**Meta-analysis of MDM2 SNP309 and lung cancer risk**

In the next step, a meta-analysis was carried out to elucidate the association between MDM2 SNP309 and lung cancer risk. Table 5 shows the 14 studies that were selected for the meta-analysis. We proceeded to pool the data from all 14 studies with the current study to carry out the meta-analysis which included 12,758 control subjects and 11,638 patient subjects.

The meta-analysis revealed that the overall data was only statistically significant in the recessive model (OR, 1.15; 95% CI, 1.04 to 1.27; \( p = 0.041 \) for heterogeneity). However, the Asian subgroup showed significant increase in risk in case of the co-dominant ([TG: OR, 1.26; 95% CI, 1.10 to 1.45; \( p = 0.144 \) for heterogeneity], [GG: OR, 1.43; 95% CI, 1.13 to 1.80; \( p = 0.003 \) for heterogeneity]), dominant (OR, 1.32; 95% CI, 1.12 to 1.56; \( p = 0.019 \) for heterogeneity), and recessive model (OR, 1.23; 95% CI, 1.05 to 1.44; \( p = 0.036 \) for heterogeneity). The Caucasian, African, hospital, and population subgroup did not show any significant risk of lung cancer (Table 6). Finally, we used

### Table 1. Distribution of the variables in lung cancer patients and controls

| Variable                  | Patients (n = 126) | Controls (n = 133) | \( p \) value |
|---------------------------|-------------------|--------------------|--------------|
| Age, yr                   | 53.52 ± 9.88      | 54.10 ± 11.95      | 0.675\( ^a \) |
| Sex                       |                   |                    |              |
| Male                      | 87 (69.05)        | 81 (60.90)         | 0.170\( ^b \) |
| Female                    | 39 (30.95)        | 52 (39.10)         |              |
| BMI, kg/m\(^2\)           | 25.57 ± 4.87      | 25.65 ± 5.62       | 0.902\( ^a \) |
| Underweight               | 7 (5.56)          | 8 (6.02)           |              |
| Normal                    | 52 (41.27)        | 59 (44.36)         |              |
| Overweight                | 67 (53.17)        | 66 (49.62)         |              |
| Smoking status            |                   |                    |              |
| Yes                       | 74 (58.73)        | 62 (46.62)         | 0.051\( ^b \) |
| No                        | 52 (41.27)        | 71 (53.38)         |              |
| Smoking history, pack-yr  | 17.32 ± 18.60     | 10.87 ± 16.17      | 0.001\( ^c,d \) |

Values are presented as mean ± SD or number (%). 
\( ^a \)Two-tailed Student’s \( t \) test. 
\( ^b \)Chi-square test. 
\( ^c \)Mann-Whitney \( U \) test/Wilcoxon rank-sum test. 
\( ^d \)Significant at 5% level of significance.

### Table 2. Distribution of alleles of MDM2 SNP309 and HWE test

| Group  | No. | MDM2 SNP309 | HWE | T  | G  |
|--------|-----|-------------|-----|----|----|
|        |     | TT | TG | GG | \( \chi^2 \) | \( p \) value |
| Patient| 126 | 47 (37.3)| 57 (45.2) | 22 (17.5) | 0.43 | 0.514 |
| Control| 133 | 75 (56.4)| 46 (34.6) | 12 (9.0)  | 1.56 | 0.212 |

Values are presented as number (%). 
MDM2, mouse double minute 2 homolog; SNP, single nucleotide polymorphism; HWE, Hardy-Weinberg equilibrium.
Table 3. Distribution of genotypes of SNP309 among lung cancer patients and healthy controls and their association with lung cancer

| Genotypes | Patients (n = 126) | Controls (n = 133) | Crude | Adjustedb |
|-----------|-------------------|-------------------|-------|-----------|
|           | p valuea | OR | 95% CI | p valuec | OR | 95% CI |
| MDM2 SNP309 | | | | | | |
| Co-dominant model | | | | | | |
| TT | 47 (37.30) | 75 (56.39) | 1.00 | Reference | 1.00 | Reference |
| TG | 57 (45.24) | 46 (34.59) | 0.012 | 1.98 | 1.16–3.37 | 0.017 | 1.93 | 1.12–3.33 |
| GG | 22 (17.46) | 12 (9.02) | 0.008 | 2.93 | 1.32–6.46 | 0.011 | 2.84 | 1.27–6.34 |
| Ptrend | | | | | | | | 0.001 |
| Dominant model | | | | | | |
| TT | 47 (37.30) | 75 (56.39) | 1.00 | Reference | 1.00 | Reference |
| TG + GG | 79 (62.70) | 58 (43.61) | 0.002 | 2.17 | 1.32–3.58 | 0.003 | 2.13 | 1.29–3.53 |
| Recessive model | | | | | | |
| TT + TG | 104 (82.54) | 121 (90.98) | 1.00 | Reference | 1.00 | Reference |
| GG | 22 (17.46) | 12 (9.02) | 0.048 | 2.13 | 1.01–4.52 | 0.053 | 2.13 | 0.99–4.58 |

Values are presented as number (%).
SNP, single nucleotide polymorphism; OR, odds ratio; CI, confidence interval; MDM2, mouse double minute 2 homolog.
a p value for simple logistic regression.
b Adjusted for age, sex, body mass index, and smoking status for use in the logistic regression model.
c p value for multiple logistic regression.

Table 4. Stratification analyses between MDM2 SNP309 genotypes and lung cancer risk

| Variable | Patients/controls | Genotypes (patients/controls) | Adjusted TG + GG vs. TT |
|----------|------------------|------------------------------|------------------------|
|          |                  | TT                           | TG + GG                |
|          |                  | Crude OR | 95% CI | Adjusted OR | 95% CI | p valuea |
| MDM2 SNP309 | | | | | | |
| Age, yr | | | | | | |
| ≤ 60 | 95/96 | 33/49 (34.74/51.04) | 62/47 (65.26/48.96) | 1.91 | 1.06–3.46 | 0.031 |
| > 60 | 31/37 | 14/26 (45.16/70.27) | 17/11 (54.84/29.73) | 3.10 | 1.09–8.85 | 0.035 |
| Sex | | | | | | |
| Male | 87/81 | 31/46 (36.54/56.79) | 56/35 (64.37/43.21) | 2.24 | 1.18–4.26 | 0.014 |
| Female | 39/52 | 16/29 (41.03/55.77) | 23/23 (58.97/44.23) | 1.78 | 0.75–4.20 | 0.191 |
| BMI, kg/m² | | | | | | |
| Underweight | 7/8 | 3/4 (42.86/50.00) | 4/4 (57.14/50.00) | 1.33 | 0.17–10.3 | 0.782 |
| Normal | 52/59 | 19/33 (58.82/62.12) | 33/26 (63.43/44.07) | 1.95 | 0.89–4.31 | 0.095 |
| Overweight | 67/66 | 25/38 (37.50/57.58) | 42/28 (62.50/42.42) | 2.19 | 1.08–4.45 | 0.030 |
| Smoking status | | | | | | |
| Yes | 74/62 | 25/36 (37.50/58.06) | 49/26 (66.22/41.04) | 2.77 | 1.36–5.68 | 0.005 |
| No | 52/71 | 22/39 (45.58/54.42) | 30/32 (57.69/45.07) | 1.74 | 0.83–3.65 | 0.142 |
| Lung cancer pathology | | | | | | |
| Small cell LC | 18/133 | 7/75 (38.89/56.39) | 11/85 (68.11/43.61) | 1.50 | 0.55–4.08 | 0.431 |
| Squamous cell LC | 75/133 | 29/75 (38.67/56.39) | 46/58 (61.33/43.61) | 1.64 | 0.94–2.86 | 0.079 |
| Adenocarcinoma | 33/133 | 11/75 (33.33/56.39) | 22/58 (66.67/43.61) | 1.80 | 0.82–3.91 | 0.142 |

Values are presented as number (%).
MDM2, mouse double minute 2 homolog; SNP, single nucleotide polymorphism; OR, odds ratio; CI, confidence interval; BMI, body mass index; LC, lung cancer.
a OR, CI, LC, and p values were calculated in the dominant model with adjustment for age, sex, BMI, and smoking status.
Table 5. Characteristics of the MDM2 SNP309 studies selected in the meta-analysis

| Study               | Country | Ethnicity | Genotyping method | Source of control | Sample size | Controls | Cases |
|---------------------|---------|-----------|-------------------|-------------------|-------------|----------|-------|
|                     |         |           |                   |                   |             | TT       | TG    | GG    |
| Hu et al. (2006)    | China   | Asian     | PIRA-PCR          | Hospital          | 717         | 274      | 538   | 271   |
| Li et al. (2006)    | USA     | Caucasian | PIRA-PCR          | Hospital          | 1,026       | 408      | 573   | 164   |
| Lind et al. (2006)  | Norway  | Caucasian | Taqman            | Population        | 341         | 161      | 207   | 44    |
| Park et al. (2006)  | Korea   | Asian     | PCR-RFLP          | Hospital          | 582         | 122      | 299   | 161   |
| Pine et al. (2006)  | USA     | Caucasian | MGB Eclipse       | Hospital          | 371         | 203      | 47    | 5     |
| Pine et al. (2006)  | USA     | African   | MGB Eclipse       | Hospital          | 133         | 182      | 187   | 52    |
| Zhang et al. (2006) | China   | Asian     | ARMS-PCR          | Population        | 1,106       | 418      | 711   | 291   |
| Liu et al. (2008)   | Canada  | Caucasian | Taqman            | Hospital          | 1,787       | 530      | 631   | 199   |
| Mittelstrass et al. (2008) | Germany | Caucasian | MALDI-TOF        | Population        | 633         | 547      | 598   | 149   |
| Chua et al. (2010)  | Singapore | Asian     | Sequencing        | Hospital          | 123         | 25       | 83    | 51    |
| Kohno et al. (2011) | Japan   | Asian     | Pyrosequencing    | Hospital          | 377         | 151      | 95    | 68    |
| Ryan et al. (2012)  | USA     | Caucasian | Taqman            | Population        | 441         | 190      | 194   | 57    |
| Ryan et al. (2012)  | USA     | African   | Taqman            | Population        | 279         | 233      | 51    | 5     |
| Ren et al. (2013)   | China   | Asian     | Taqman            | Hospital          | 764         | 335      | 472   | 176   |
| Gansmo et al. (2015)| Norway  | Caucasian | LightSNiP         | Population        | 3,749       | 1,464     | 1,783 | 502   |
| Li et al. (2017)    | China   | Asian     | Sequencing        | Hospital          | 196         | 51       | 101   | 44    |

MDM2, mouse double minute 2 homolog; SNP, single nucleotide polymorphism; PIRA, primer-introduced restriction analysis; PCR, polymerase chain reaction; RFLP, restriction fragment length polymorphism; MGB, minor groove binder; ARMS, amplification refractory mutation system; MALDI-TOF, matrix-assisted laser desorption/ionization-time of flight.
Galbraith plots to evaluate the overall heterogeneity of the pooled data. In addition, Beggs’s rank correlation test and Egger’s linear regression test did not indicate any publication bias in any of the models used (co-dominant model [TG vs. TT: \( t = 1.49, p = 0.157 \); GG vs. TT: \( t = 0.91, p = 0.379 \]), dominant model [\( t = 1.48, p = 0.160 \]), and recessive model [\( t = 0.49, p = 0.628 \)].

**DISCUSSION**

Lung cancer is a disease that thrives in this age of industry. The sufferers of lung cancer are endless, and the numbers seem to be growing rapidly each year. SNPs are of particular interest in this field as many SNPs have been associated with increased risk of cancer [29]. The MDM2 gene is one such example where the effect of SNPs has been known to increase the risk of lung cancer. Several studies have reported that MDM2 down-regulates the p53 protein levels by ubiquitinylation and subsequent proteasomal degradation [30-32]. Moreover, MDM2 is suspected to induce tumorigenesis via p53-independent pathways due to its p53-independent overexpression [33,34].

Hu et al. [32] reported that SNPs in the MDM2 gene decreases p53 levels and decrease the efficiency of the p53 pathway. SNPs such as MDM2 SNP309 T>G (rs2279744) are of particular interest as they are known to influence the risk of cancer. The transcription factor replace with SP1 preferentially binds to the G allele compared to the T allele and hence increases the expression of MDM2. Increased expression of MDM2 reduces the tumor-suppressor function of p53 and can contribute to the development of cancer [35]. SNP309 is known to reduce the expression of p53, increasing the risks of cancer. In Bangladesh, it has been reported that P53 codon 72 polymorphisms are a risk factor for lung cancer [10]. Thus, we hypothesized that the aforementioned SNP could affect the risk of lung cancer, and factors such as age, sex, BMI, and smoking status could aggravate the effects.

Our data indicate that people carrying either TG or GG alleles of SNP309 are at a 2.17 times increased risk of lung cancer when compare to people carrying TT (Table 3). Further analysis revealed that older people are at a 3.1 times higher risk when carrying SNP309, which could potentially explain the increased incidence of lung cancer in the elderly (Table 4). It was also observed that men were at 2.24 times higher risk in comparison to female when carrying SNP309, which may reflect the accumulative effects of exposure to higher levels of mutagens [36-38]. Many studies have reported that smokers carrying SNP309 are at a significantly increased risk of lung cancer, and our results are in agreement with the studies showing 2.77 times higher risk with smoking, as well [39]. In addition, we have shown that the risk of lung cancer increases with obesity as well as smoking habit, age and in males. Our study indicates that the association follows a dominant model on G allele. However,

---

**Table 6. Meta-analysis of MDM2 SNP309 on lung cancer risk**

| Variable     | No. | TG vs. TT OR (95% CI) p value | GG vs. TT OR (95% CI) p value | TG + GG vs. TT OR (95% CI) p value | GG vs. TT + TG OR (95% CI) p value |
|--------------|-----|------------------------------|------------------------------|------------------------------------|-----------------------------------|
| Total        | 17  | 1.06 (0.95–1.18) 0.001        | 1.22 (1.04–1.43) 0.001        | 1.10 (0.97–1.24) 0.001              | 1.15 (1.04–1.27) 0.041            |
| Ethnicity    |     |                              |                              |                                    |                                   |
| Asian        | 8   | 1.26 (1.10–1.45) 0.144        | 1.43 (1.13–1.80) 0.003        | 1.32 (1.12–1.56) 0.019              | 1.23 (1.05–1.44) 0.036            |
| Caucasian    | 7   | 0.91 (0.84–0.98) 0.356        | 1.01 (0.88–1.16) 0.204        | 0.93 (0.85–1.02) 0.199              | 1.05 (0.95–1.18) 0.374            |
| African      | 2   | 1.03 (0.79–1.33) 0.472        | 1.21 (0.80–1.85) 0.509        | 1.05 (0.82–1.35) 0.357              | 1.17 (0.79–1.75) 0.557            |
| Source of control | |                              |                              |                                    |                                   |
| Population   | 6   | 1.01 (0.85–1.20) 0.008        | 1.22 (0.92–1.61) 0.002        | 1.05 (0.87–1.28) 0.001              | 1.19 (0.99–1.43) 0.072            |
| Hospital     | 11  | 1.09 (0.94–1.28) 0.002        | 1.22 (0.99–1.50) 0.001        | 1.13 (0.96–1.34) 0.001              | 1.13 (0.99–1.28) 0.092            |

MDM2, mouse double minute 2 homolog; SNP, single nucleotide polymorphism; OR, odds ratio; CI, confidence interval.

*Number of studies tested.

b p value of Q-test for heterogeneity.

c When p value for Q-test < 0.10, random-effects model was used; else, the fixed-effects model was used.
our sample size was relatively small because most of the lung cancer patients were unwilling to provide consent. But the sample size is quite sufficient for such study as the results were adjusted for the small sample size using various robust statistical calculations. Previously, Park et al. [15], 2006 showed that people carrying GG at SNP309 were at greater risk compared to people carrying TT for lung adenocarcinoma (GG vs. TT: OR, 1.91; 95% CI, 1.16 to 3.14; $p = 0.01$). Despite this co-dominant model, the other models were insignificant [15]. On the other hand, Liu et al. [18] 2008 reported no significant association between SNP309 and non-small cell lung cancer in their stratification analyses. Overall, the dichotomy of which pathological subtype is affected by MDM2 SNP309 remains at large. In our study, SNP309 showed no significant association with lung cancer subtypes in all models.

We carried out the meta-analysis by pooling the published data with our own data in order to account for the varying effects observed in other studies. The meta-analysis revealed that select ethnic population such as Caucasians and Africans are unaffected by SNP309, while Asians are at considerable risk of lung cancer when carrying SNP309 TG or GG allele (Table 6). These effects are in accordance with the meta-analysis studies published by Zhuo et al. [11] and He et al. [40].

In summary, our data suggest that MDM2 SNP309 is associated with an increased risk of lung cancer especially in the Asian population, which was in agreement with our meta-analysis. Such risk could be increased in older people, overweight people, men, and smokers when carrying SNP309 G allele. Further validation with larger sample size from different ethnicities and sources, and a detailed molecular mechanism of the effect of SNP309 on MDM2 expression are required to elucidate the role of these polymorphisms.

**Conflict of interest**

No potential conflict of interest relevant to this article was reported.

**Acknowledgments**

The authors wish to acknowledge Neil Shephard from the Clinical Trials Research Unit, University of Sheffield for providing some of the Stata v14.1 code packages. The authors are grateful to Dr. Margaret Beucher of Utah Valley University, Orem, Utah, USA, for critically reviewing the article. We would also like to thank all the patient and control subjects for their participation. We are grateful to the Higher Education Quality Enhancement Project (HEQEP) authority for providing essential facilities at the Department of Genetic Engineering and Biotechnology, University of Dhaka for this research.

**REFERENCES**

1. Ozlu T, Bulbul Y. Smoking and lung cancer. Tuberk Toraks 2005;53:200-209.
2. Bjartveit K, Tverdal A. Health consequences of smoking 1-4 cigarettes per day. Tob Control 2005;14:315-320.
3. Jemal A, Tiwari RC, Murray T, et al. Cancer statistics, 2004. CA Cancer J Clin 2004;54:8-29.
4. Dela Cruz CS, Tanoue LT, Matthay RA. Lung cancer: epidemiology, etiology, and prevention. Clin Chest Med 2011;32:605-644.
5. Schottenfeld D. The epidemiology of cancer: an overview. Cancer 1981;47(5 Suppl):1095-1108.
6. Ridge CA, McErlean AM, Ginsberg MS. Epidemiology of lung cancer. Semin Intervent Radiol 2013;30:93-98.
7. Carreras-Torres R, Johansson M, Haycock PC, et al. Obesity, metabolic factors and risk of different histological types of lung cancer: a Mendelian randomization study. PLoS One 2017;12:e017875.
8. Wade M, Wong ET, Tang M, Stommel JM, Wahl GM. Hdmx modulates the outcome of p53 activation in human tumor cells. J Biol Chem 2006;281:33036-33044.
9. Iwakuma T, Lozano G. MDM2, an introduction. Mol Cancer Res 2003;1:1993-1000.
10. Chowdhury MK, Moniruzzaman M, Emran AA, Mostafa MG, Kuddus RH, Uddin MA. TP53 codon 72 polymorphisms and lung cancer risk in the Bangladesh population. Asian Pac J Cancer Prev 2015;16:3493-3498.

**KEY MESSAGE**

1. The G allele of mouse double minute 2 homolog (MDM2) single nucleotide polymorphism (SNP) 309 is associated with increased risk of lung cancer development in Asian population.
2. Age, sex, smoking status, and body mass index can contribute further to enhance lung cancer risk in people with MDM2 SNP309 G allele.
11. Zhuo W, Zhang L, Zhu B, Ling J, Chen Z. Association of MDM2 SNP309 variation with lung cancer risk: evidence from 7106 cases and 8456 controls. PLoS One 2012;7:e41546.

12. Hu Z, Ma H, Lu D, et al. Genetic variants in the MDM2 promoter and lung cancer risk in a Chinese population. Int J Cancer 2006;118:1275-1278.

13. Li G, Zhai X, Zhang Z, Chamberlain RM, Spitz MR, Wei Q. MDM2 gene promoter polymorphisms and risk of lung cancer: a case-control analysis. Carcinogenesis 2006;27:2028-2033.

14. Lind H, Zienolddiny S, Ekstrom PO, Skaug V, Haugen A. Association of a functional polymorphism in the promoter of the MDM2 gene with risk of nonsmall cell lung cancer. Int J Cancer 2006;118:1275-1278.

15. Park SH, Choi JE, Kim EJ, et al. MDM2 309T>G polymorphism and risk of lung cancer in a Korean population. Lung Cancer 2006;54:19-24.

16. Pine SR, Mechanic LE, Bowman ED, et al. MDM2 SNP309 and SNP354 are not associated with lung cancer risk. Cancer Epidemiol Biomarkers Prev 2006;15:1559-1561.

17. Zhang X, Miao X, Guo Y, et al. Genetic polymorphisms in cell cycle regulatory genes MDM2 and TP53 are associated with susceptibility to lung cancer. Hum Mutat 2006;27:110-117.

18. Liu G, Wheatley-Price P, Zhou W, et al. Genetic polymorphisms of MDM2, cumulative cigarette smoking and nonsmall cell lung cancer risk. Int J Cancer 2006;122:915-918.

19. Mittelstrass K, Sauter W, Rosenberger A, et al. Early onset lung cancer, cigarette smoking and the SNP309 of the murine double minute-2 (MDM2) gene. BMC Cancer 2008;8:110-117.

20. Chua HW, Ng D, Choo S, et al. Effect of MDM2 SNP309 and p53 codon 72 polymorphisms on lung cancer risk and survival among non-smoking Chinese women in Singapore. BMC Cancer 2008;8:213.

21. Ries S, Biederer C, Woods D, et al. Opposing effects of Ras on p53: transcriptional activation of mdm2 and induction of p19ARF. Cell 2000;103:311-320.

22. Ryan BM, Calhoun KM, Pine SR, et al. MDM2 SNP285 does not antagonize the effect of SNP309 in lung cancer. Int J Cancer 2012;131:2710-2716.

23. Ren YW, Yin ZH, Wan Y, et al. P53 Arg72Pro and MDM2 SNP309 polymorphisms cooperate to increase lung adenocarcinoma risk in Chinese female non-smokers: a case control study. Asian Pac J Cancer Prev 2013;14:5415-5420.

24. Gansmo LB, Knappskog S, Romundstad P, Hveem K, Vatten L, Lonning PE. Influence of MDM2 SNP309 and SNP285 status on the risk of cancer in the breast, prostate, lung and colon. Int J Cancer 2013;133:103-107.

25. Li W, Wang SS, Deng J, Tang JX. Association of p73 gene G4C14-A4T14 polymorphism and MDM2 gene SNP309 with non-small cell lung cancer risk in a Chinese population. Oncol Lett 2017;14:1817-1822.

26. Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 1959;22:719-728.

27. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997;315:629-634.

28. Gauderman WJ, Murcray C, Gilliland F, Conti DV. Testing association between disease and multiple SNPs in a candidate gene. Genet Epidemiol 2007;31:383-395.

29. Grossman SR, Perez M, Kung AL, et al. p500/MDM2 complexes participate in MDM2-mediated p53 degradation. Mol Cell 1998;2:405-415.

30. Dai MS, Sun XX, Lu H. Aberrant expression of nucleostemin activates p53 and induces cell cycle arrest via inhibition of MDM2. Mol Cell Biol 2008;28:4365-4376.

31. Hu W, Feng Z, Ma L, et al. A single nucleotide polymorphism in the MDM2 gene disrupts the oscillation of p53 and MDM2 levels in cells. Cancer Res 2007;67:2757-2765.

32. Xiao ZX, Chen J, Levine AJ, et al. Interaction between the retinoblastoma protein and the oncoprotein MDM2. Nature 1995;375:694-698.

33. Ries S, Biederer C, Woods D, et al. Opposing effects of Ras on p53: transcriptional activation of mdm2 and induction of p19ARF. Cell 2000;103:311-320.

34. Han JY, Lee GK, Jang DH, Lee SY, Lee JS. Association of p53 codon 72 polymorphism and MDM2 SNP309 with clinical outcome of advanced nonsmall cell lung cancer. Cancer 2008;113:799-807.

35. Sun S, Schiller JH, Gazdar AF. Lung cancer in never smokers: a different disease. Nat Rev Cancer 2007;7:778-790.

36. Subramanian J, Govindan R. Lung cancer in never smokers: a review. J Clin Oncol 2007;25:560-570.
38. Mulvihill JJ. Preconception exposure to mutagens: medical and other exposures to radiation and chemicals. J Community Genet 2012;3:205-211.

39. Bai J, Dai J, Yu H, Shen H, Chen F. Cigarette smoking, MDM2 SNP309, gene-environment interactions, and lung cancer risk: a meta-analysis. J Toxicol Environ Health A 2009;72:677-682.

40. He W, Long J, Xian L, et al. MDM2 SNP309 polymorphism is associated with lung cancer risk in women: a meta-analysis using METAGEN. Exp Ther Med 2012;4:569-576.